2024 World Conference on Lung Cancer (WCLC) - Posters-P1.02C.02 NIR-II Mediates Cancer Nanocomposite Vaccines for Lymph Node Targeted Delivery and Enhanced Immunotherapy

P1.02C.02 NIR-II Mediates Cancer Nanocomposite Vaccines for Lymph Node Targeted Delivery and Enhanced Immunotherapy

Pdf Summary

This study explores a nanovaccine approach for treating non-small cell lung cancer (NSCLC), which remains a significant challenge due to its high morbidity and mortality rates. Traditional immunotherapy shows promise but often lacks efficiency and precision, necessitating better diagnostic and treatment strategies. The research focuses on Au/VNPR848, an in situ programmable nanovaccine, which aims to enhance the efficacy of cancer vaccines while minimizing systemic side effects.<br /><br />The nanovaccine utilizes NIR-II (near-infrared II) technology to target lymph nodes with nanoparticles. This method aims to deliver tumor antigens and adjuvants to lymph nodes more effectively, activating antigen-presenting cells and inducing specific anti-tumor immune responses. The study used an animal model to demonstrate the nanovaccine's capability in targeting lymph nodes and subsequently stimulating an immune response that inhibits tumor growth.<br /><br />The research outlined several key findings: through in vivo experiments, the nanovaccine showed specific accumulation in lymph nodes and enhanced the uptake by dendritic cells (DCs), which are crucial for effective immune response. Flow cytometry analysis indicated that the nanovaccine promoted DC maturation, a vital step in the immune system's attack against cancer cells. Furthermore, the study observed suppressed primary and distant tumor growth in NSCLC models, suggesting that this targeted vaccine delivery system could be a viable strategy for managing solid tumors like lung cancer.<br /><br />In conclusion, the nanovaccine strategy effectively integrates antigen generation and delivery to activate the tumor-immune cycle and subsequent T cell immune response. This approach provides a basis for developing in situ, personalized vaccination programs that could become valuable tools in clinical cancer treatment. The research promises advancements in the targeted treatment of lung cancer through innovative nanotechnology.

Asset Subtitle

Lintong Yao

Meta Tag

Speaker Lintong Yao

Topic Tumor Biology – Preclinical Biology

Keywords

nanovaccine

non-small cell lung cancer

NSCLC

immunotherapy

Au/VNPR848

NIR-II technology

lymph nodes

dendritic cells

tumor-immune cycle

personalized vaccination